Galmed Pharmaceuticals (GLMD) Stock Forecast, Price Target & Predictions
GLMD Stock Forecast
Galmed Pharmaceuticals stock forecast is as follows: a rating consensus of 'Hold', based on 7 wall street analysts offering a 1-year stock forecast.
GLMD Analyst Ratings
According to 7 Wall Street analysts, Galmed Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for GLMD stock is 0 'Strong Buy' (0.00%), 3 'Buy' (42.86%), 4 'Hold' (57.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 24, 2023 | Maxim Group | - | Buy | Upgrade |
| Jul 24, 2023 | Raymond James | - | Market Perform | Downgrade |
| Jul 24, 2023 | BTIG | - | Buy | Upgrade |
| Jul 24, 2023 | Goldman Sachs | - | Buy | Upgrade |
| Jul 24, 2023 | Credit Suisse | - | Neutral | Downgrade |
| Jul 24, 2023 | Piper Sandler | - | Neutral | Downgrade |
| Jul 24, 2023 | Exane BNP Paribas | - | Neutral | Downgrade |
Galmed Pharmaceuticals's last stock rating was published by Maxim Group on Jul 24, 2023. The company Upgrade its GLMD rating from "null" to "Buy".
Galmed Pharmaceuticals Financial Forecast
Galmed Pharmaceuticals Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | $1.50M | $270.00K | $268.00K | $273.00K | $270.00K | $268.00K | $193.00K |
| Avg Forecast | - | - | - | - | - | $83.33K | $4.20M | $253.13K | $346.17K | $294.84K | $320.00K | $352.63K | $217.74K |
| High Forecast | - | - | - | - | - | $83.33K | $5.04M | $303.75K | $415.40K | $353.81K | $384.00K | $423.16K | $261.29K |
| Low Forecast | - | - | - | - | - | $83.33K | $3.36M | $202.50K | $276.93K | $235.87K | $256.00K | $282.10K | $174.19K |
| # Analysts | - | - | - | 1 | - | 3 | 9 | 18 | 19 | 20 | 16 | 20 | 13 |
| Surprise % | - | - | - | - | - | - | 0.36% | 1.07% | 0.77% | 0.93% | 0.84% | 0.76% | 0.89% |
Galmed Pharmaceuticals's average Quarter revenue forecast for Mar 19 based on 3 analysts is $83.33K, with a low forecast of $83.33K, and a high forecast of $83.33K. GLMD's average Quarter revenue forecast represents a -94.44% decrease compared to the company's last Quarter revenue of $1.50M (Sep 18).
Galmed Pharmaceuticals EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | 3 | 9 | 18 | 19 | 20 | 16 | 20 | 13 |
| EBITDA | - | - | - | - | - | $-3.48M | $-816.00K | $-2.63M | $-2.45M | $-2.74M | $-2.63M | $-3.10M | $-3.67M |
| Avg Forecast | - | - | - | - | - | $-4.64M | $-1.21M | $-2.46M | $-3.16M | $-2.96M | $-3.12M | $-4.08M | $-4.15M |
| High Forecast | - | - | - | - | - | $-3.71M | $-965.21K | $-1.97M | $-2.53M | $-2.37M | $-2.50M | $-3.27M | $-3.32M |
| Low Forecast | - | - | - | - | - | $-5.56M | $-1.45M | $-2.95M | $-3.79M | $-3.55M | $-3.74M | $-4.90M | $-4.98M |
| Surprise % | - | - | - | - | - | 0.75% | 0.68% | 1.07% | 0.77% | 0.93% | 0.84% | 0.76% | 0.89% |
undefined analysts predict GLMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Galmed Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
Galmed Pharmaceuticals Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | 3 | 9 | 18 | 19 | 20 | 16 | 20 | 13 |
| Net Income | - | - | - | - | - | $-3.49M | $-959.00K | $-2.69M | $-2.51M | $-2.80M | $-2.69M | $-3.16M | $-3.83M |
| Avg Forecast | $808.57K | $704.27K | $8.61M | $-1.61M | $-1.87M | $-4.02M | $-1.42M | $-2.52M | $-3.24M | $-3.03M | $-3.19M | $-4.16M | $-4.32M |
| High Forecast | $808.57K | $704.27K | $8.61M | $-1.61M | $-1.87M | $-3.21M | $-1.13M | $-2.01M | $-2.59M | $-2.42M | $-2.55M | $-3.33M | $-3.46M |
| Low Forecast | $808.57K | $704.27K | $8.61M | $-1.61M | $-1.87M | $-4.82M | $-1.70M | $-3.02M | $-3.88M | $-3.63M | $-3.83M | $-4.99M | $-5.19M |
| Surprise % | - | - | - | - | - | 0.87% | 0.68% | 1.07% | 0.77% | 0.93% | 0.84% | 0.76% | 0.89% |
Galmed Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GLMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Galmed Pharmaceuticals SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | 3 | 9 | 18 | 19 | 20 | 16 | 20 | 13 |
| SG&A | - | - | - | - | - | $771.00K | $987.00K | $1.10M | $883.00K | $697.00K | $624.00K | $789.00K | $656.00K |
| Avg Forecast | - | - | - | - | - | $102.98K | $1.46M | $312.79K | $427.76K | $364.34K | $395.43K | $435.75K | $269.07K |
| High Forecast | - | - | - | - | - | $102.98K | $1.75M | $375.35K | $513.32K | $437.21K | $474.52K | $522.90K | $322.88K |
| Low Forecast | - | - | - | - | - | $102.98K | $1.17M | $250.23K | $342.21K | $291.47K | $316.34K | $348.60K | $215.25K |
| Surprise % | - | - | - | - | - | 7.49% | 0.68% | 3.53% | 2.06% | 1.91% | 1.58% | 1.81% | 2.44% |
Galmed Pharmaceuticals's average Quarter SG&A projection for Sep 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to GLMD last annual SG&A of $771.00K (Mar 19).
Galmed Pharmaceuticals EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | Mar 17 | Sep 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | - | 3 | 9 | 18 | 19 | 20 | 16 | 20 | 13 |
| EPS | - | - | - | - | - | $-0.17 | $-0.05 | $-0.17 | $-0.17 | $-0.23 | $-0.22 | $-0.26 | $-0.34 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.32 | $-0.30 | $-3.02 | $-0.21 | $-0.15 | $-0.31 | $-0.27 | $-0.32 | $-0.50 | $-0.44 |
| High Forecast | $1.54 | $1.34 | $1.58 | $-0.32 | $-0.30 | $-3.02 | $-0.17 | $-0.12 | $-0.25 | $-0.22 | $-0.26 | $-0.40 | $-0.35 |
| Low Forecast | $1.54 | $1.34 | $1.58 | $-0.32 | $-0.30 | $-3.02 | $-0.25 | $-0.18 | $-0.37 | $-0.32 | $-0.38 | $-0.60 | $-0.53 |
| Surprise % | - | - | - | - | - | 0.06% | 0.24% | 1.13% | 0.55% | 0.85% | 0.69% | 0.52% | 0.77% |
According to undefined Wall Street analysts, Galmed Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GLMD previous annual EPS of $NaN (undefined).
Galmed Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KOD | Kodiak Sciences | $2.31 | $32.80 | 1319.91% | Buy |
| AKBA | Akebia Therapeutics | $1.35 | $6.50 | 381.48% | Buy |
| PDSB | PDS Bio | $2.93 | $9.00 | 207.17% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| ADAP | Adaptimmune Therapeutics | $1.09 | $2.83 | 159.63% | Buy |
| AFMD | Affimed | $3.76 | $7.50 | 99.47% | Buy |
| LPTX | Leap Therapeutics | $2.81 | $5.50 | 95.73% | Buy |
| GLMD | Galmed Pharmaceuticals | $3.02 | $5.00 | 65.56% | Buy |
| MREO | Mereo BioPharma Group | $4.32 | $6.75 | 56.25% | Buy |
| ABEO | Abeona Therapeutics | $5.55 | $6.00 | 8.11% | Buy |
| ADVM | Adverum Bio | $6.76 | $7.00 | 3.55% | Buy |
GLMD Forecast FAQ
Is Galmed Pharmaceuticals a good buy?
No, according to 7 Wall Street analysts, Galmed Pharmaceuticals (GLMD) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 42.86% of GLMD's total ratings.
What are Galmed Pharmaceuticals's analysts' financial forecasts?
GLMD's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-3.488M (high $-3.488M, low $-3.488M), average SG&A $0 (high $0, low $0), and average EPS is $-0.62 (high $-0.62, low $-0.62).
Did the GLMD's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Sep 2018), Galmed Pharmaceuticals's revenue was $1.5M, missing the average analysts' forecast of $4.2M by -64.29%. The company's EBITDA was $-816K, missing the average prediction of $-1.207M by -32.37%. Galmed Pharmaceuticals's net income was $-959K, missing the average estimation of $-1.418M by -32.37%. The company's SG&A was $987K, missing the average forecast of $1.46M by -32.37%. Lastly, the company's EPS was $-0.05, missing the average prediction of $-0.21 by -76.19%